To answer the question of why we are not at $2-3 now, it is because risk is a very heavy weight. Retail investors tend to look mostly at profit potential. Professional and very large funds are mostly risk managers. They will wait until risk at a low level and that is usually when the FDA clears the path. From now til then it is retail investors only and no institutional support. Bigger funds don't want to ever explain to their investors that they put their money in a tiny one product biotech no matter what the science says. When the FDA accepts a BLA, it is over 90% certain that it will be approved. we don't need to look at a calendar and figure out when the day is that Leronlimab will be in pharmacies, we will see the stock price reaction to that reality long before.